Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
Clinical trial NCT03242915 · COMPLETED
Trial details
- NCT number
- NCT03242915
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-03
- Primary completion
- 2025-02-20
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.